Impact Factor
3.33
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.19
728 total citations
h5-index
31
h5 depth signal
Cited share
72.7%
266 of 366
Total citations
728
Citation footprint
Metric signal
2.16
External metric anchor
Self-citation
4.4%
32 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
516
China
356
Brazil
185
Japan
152
United Kingdom
146
Citing Fields of Research
Musculoskeletal Disorders
1,630
Auto-Inflammatory Disorders
660
Immunology
514
Hematology
478
Kidney Diseases
171
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,819
Articles tracked across the journal lifetime
Indexed publication set
366
266 cited publications
Last 12 months
186
15.5 publications/month
Open access share
11.8%
22 OA publications in the last year
Leading citing country
United States
516 citing publications
Leading citing field
Musculoskeletal Disorders
1,630 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Nov. 1991-
v1n1,Nov. 1991-
Active Coverage
Research Focus & Classification
Indexed Subjects
Musculoskeletal Disorders
Broad Categories
Rheumatology
Musculoskeletal Disorders
MeSH Descriptors
Lupus Erythematosus, Systemic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/09612033261499215
Open DOI
How relationships with exercise change: A qualitative study on the influences of exercise decision-making with systemic lupus erythematosus and cardiovascular disease
Background: Greater than 50% of individuals with systemic lupus erythematosus (SLE) will develop cardiovascular disease (CVD). Moderate-intensity aerobic exercise significantly reduces CVD risk, morbidity, and mortality, yet most persons...
02
DOI 10.1177/09612033261496128
Open DOI
The “living well with lupus” lifestyle intervention: Effects on gut microbiota in patients with systemic lupus erythematosus and high cardiovascular risk
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with increased cardiovascular risk and gut microbiota dysbiosis. Although lifestyle can modulate the microbiome, the impact of multidisciplinary intervent...
03
DOI 10.1177/09612033261499150
Open DOI
Associations between methodological quality and representation in clinical trials of systemic lupus erythematosus therapies
Background: Randomized clinical trials support drug development and uptake of new therapies for systemic lupus erythematosus (SLE). However, challenges to conducting high-quality clinical trials have been noted, including underrepresenta...
04
DOI 10.1177/09612033261498255
Open DOI
The impact of non-medical determinants of health on patient-reported outcomes in pediatric lupus: A CARRA registry study
Objectives: Social determinants of health (SDOH) and race are associated with disease activity, including lower achievement of the low lupus disease activity state (LLDAS), but it is unknown whether these factors are associated with pati...
05
DOI 10.1177/09612033261498258
Open DOI
Serum cell adhesion molecules (CAMs) NrCAM and P-Cadherin as novel biomarkers in lupus nephritis
Objective: This study aimed to identify novel serum biomarkers for lupus nephritis (LN) and evaluate their potential for improving diagnosis, monitoring disease activity, and understanding LN pathogenesis. Methods: A cell adhesion molecu...
06
DOI 10.1177/09612033261494023
Open DOI
Experiences of pregnancy and family planning in patients with antiphospholipid antibodies and antiphospholipid syndrome
Background: Women with antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are at increased risk of pregnancy complications. Routinely reported endpoints primarily captures what happens medically but provide limited ins...
07
DOI 10.1177/09612033261493822
Open DOI
Beyond monospecificity in systemic lupus erythematosus: Emerging roles of bispecific and trispecific antibodies
Purpose: Targeted biologic therapy has changed the management of systemic lupus erythematosus (SLE), including lupus nephritis (LN), but incomplete response, relapse, glucocorticoid dependence, and refractory organ disease remain common....
08
DOI 10.1177/09612033261496577
Open DOI
Characteristics and associated risk factors of opportunistic infection in children with systemic lupus erythematosus in under-resourced areas
Objective: Infection is a major factor in morbidity and mortality among pediatric systemic lupus erythematosus (SLE) patients, particularly opportunistic infections (OI), which can result in severe clinical outcomes. There is a scarcity ...
09
DOI 10.1177/09612033261494026
Open DOI
Gaps in cervical cancer screening and HPV vaccination in women with systemic lupus erythematosus
10
DOI 10.1177/09612033261495245
Open DOI
Multimarker profiling of immune and vascular disregulation in antiphospholipid syndrome and systemic lupus erythematosus
Background: Antiphospholipid syndrome (APS) is an autoimmune condition marked by thrombosis and pregnancy complications caused by antiphospholipid antibodies (aPL). This study evaluates immunological, inflammatory, and endothelial biomar...
Bibliographical & Catalog Notes
Supplements accompany some vols.
Also issued online.
Vol. 3, no. 1 (JAN 1994)19960129 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper